Sunday, July 21, 2024

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Search

Guillain-Barré Syndrome ‘More Common Than Expected’ in Early RSV Vaccine Trial

Guillain-Barré Syndrome ‘More Common Than Expected’ in Early RSV Vaccine Trial

Reports of the nervous system disorder Guillain-Barré syndrome (GBS) were “more common than expected” in the older adult population who received the new vaccine for respiratory syncytial virus (RSV). The data, reported by the U.S. Centers for Disease Control and Prevention (CDC), matched trial data reported earlier this year.1 GBS is a “polio-like” inflammatory autoimmune […]

CDC Pushes Pfizer’s Pentavalent Meningococcal Vaccine

CDC Pushes Pfizer’s Pentavalent Meningococcal Vaccine

On Oct. 20, 2023, Pfizer, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its new pentavalent meningococcal vaccine, Penbraya, which targets five meningococcal serogroups (A, B, C, W and Y) that most commonly cause meningococcal disease in adolescents and young adults 10-25 years old. Penbraya, is recommended to be given in two […]

RSV Vaccines for Senior Adults Linked to Guillain-Barré Syndrome

RSV Vaccines for Senior Adults Linked to Guillain-Barré Syndrome

On Feb. 29, 2024, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) presented a preliminary analysis that showed that 23 adults over the age of 65 who received a respiratory syncytial virus (RSV) vaccine developed Guillain-Barré syndrome (GBS).1 When a person develops GBS, including after an infection or […]

Some Children Suffered Seizures Following mRNA COVID Shots

Some Children Suffered Seizures Following mRNA COVID Shots

A 2023 analysis published by researchers from Kaiser Permanente and the U.S. Centers for Disease Control and Prevention (CDC) in the journal Pediatrics compared vaccine adverse outcomes following administration of Pfizer/BioNTech’s Comirnaty messenger RNA (mRNA) COVID-19 shot and Moderna/NIAID’s Spikevax mRNA COVID-19 shot among recipients under five years old for a period of 1-21 days […]

Guillain-Barré Syndrome Linked to the RSV Vaccine

Guillain-Barré Syndrome Linked to the RSV Vaccine

The potential risk of Guillain-Barré syndrome (GBS) developing after receipt of Pfizer’s respiratory experimental syncytial virus (RSV) vaccine have prompted the U.S. Food and Drug Administration (FDA) to request that Pfizer conduct a post-marketing safety study if the vaccine is approved for use in the United States this spring.1 The RSV vaccine manufactured by GlaxoSmithKline […]

Search in Site

To search in site, type your keyword and hit enter

Search